Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Epinastine Syrup vs Tablets in Healthy Volunteers
NCT02260063Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 1998
- Primary completion
- Jan 1999
- Modality
- Small Molecules
01
Overview
Phase 1 trial of epinastine in allergic rhinitis (AR) and urticaria, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the curve of plasma concentration at 24 hours and Absorption rate Cpmax/AUC at 24 hours. Started Nov 1998; status: completed.
02
Drugs
epinastine
03
Conditions
allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on NCT02260063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260063.